Not yet recruitingPhase 2NCT06274879
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Principal Investigator
- Reiner Prof. Dr. med. WiestInselspital Bern University Hospital
- Intervention
- Gemcitabin, Cisplatin and Durvalumab(drug)
- Enrollment
- 36 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Inselspital Bern University Hospital, Bern, Canton of Bern, Switzerland
Collaborators
Swiss Cancer League
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06274879 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University